Omega Funds Closes $647M Life Sciences Venture Capital Fund VIII

Omega Funds, a venture capital firm specializing in life sciences, has closed its eighth fund with $647 million in capital commitments, exceeding its initial $600 million target. This latest fund brings the firm's total capital raised to $2.5 billion since 2004 and will continue to support innovative life sciences companies in the U.S. and Europe focusing on severe, unmet medical needs across oncology, immunology, rare diseases, medical devices, and precision medicine. Omega's portfolio boasts 52 commercialized products, 50 successful mergers and acquisitions, and 47 public listings, with notable exits including Scorpion Therapeutics acquired by Eli Lilly and EyeBio acquired by Merck. Managing Director Francesco Draetta emphasized that the firm’s broad investment strategy is well-positioned to navigate current macroeconomic and policy uncertainties, while Founder Otello Stampacchia highlighted the fund’s oversubscription as a testament to investor confidence. Despite a general decline in biotech venture funding, Omega continues to actively invest in late-stage financings and company creation, partnering with entrepreneurs and co-investors to advance transformative treatments.